Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110810 | 1.00 | THRB (0.38) | THRBTHRAAGTR1ALDH1A1CDC25A | |
| SCHEMBL5113888 | 0.97 | ALDH1A1 (0.37) | THRBTHRAAGTR1ALDH1A1HPGD | |
| SCHEMBL5126345 | 0.97 | ALDH1A1 (0.37) | THRBTHRAAGTR1ALDH1A1HPGD | |
| SCHEMBL5118475 | 0.93 | THRB (0.39) | THRBTHRAALDH1A1CDC25AHPGD | |
| SCHEMBL5118477 | 0.93 | THRB (0.39) | THRBTHRAALDH1A1CDC25AHPGD | |
| SCHEMBL5113812 | 0.93 | THRB (0.39) | THRBTHRAALDH1A1CDC25AHPGD | |
| SCHEMBL5113816 | 0.93 | THRB (0.39) | THRBTHRAALDH1A1CDC25AHPGD | |
| SCHEMBL5116900 | 0.92 | THRB (0.38) | THRBTHRAALDH1A1CDC25AHPGD | |
| SCHEMBL5116901 | 0.92 | THRB (0.38) | THRBTHRAALDH1A1CDC25AHPGD | |
| SCHEMBL5113796 | 0.91 | PARK7 (0.38) | AGTR1ALDH1A1HPGDALOX15MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | THRB 491/4885THRA 559/4885AGTR1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.